Boston Scientific Co. (NYSE:BSX) is Miura Global Management LLC's 5th Largest Position

Miura Global Management LLC decreased its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 27.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 80,000 shares of the medical equipment provider's stock after selling 30,000 shares during the period. Boston Scientific makes up 7.7% of Miura Global Management LLC's holdings, making the stock its 5th biggest holding. Miura Global Management LLC's holdings in Boston Scientific were worth $6,704,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Boston Scientific by 4.4% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider's stock worth $345,205,000 after acquiring an additional 173,034 shares during the last quarter. BDF Gestion purchased a new stake in Boston Scientific in the 2nd quarter valued at about $3,570,000. Brookstone Capital Management grew its position in shares of Boston Scientific by 389.1% during the 2nd quarter. Brookstone Capital Management now owns 69,945 shares of the medical equipment provider's stock valued at $5,414,000 after acquiring an additional 55,645 shares during the period. HWG Holdings LP bought a new position in shares of Boston Scientific during the 2nd quarter valued at approximately $482,000. Finally, PGGM Investments grew its position in shares of Boston Scientific by 9.6% during the 2nd quarter. PGGM Investments now owns 117,794 shares of the medical equipment provider's stock valued at $9,071,000 after acquiring an additional 10,366 shares during the period. 89.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BSX has been the subject of several analyst reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Boston Scientific in a report on Wednesday, November 27th. Canaccord Genuity Group raised their price objective on shares of Boston Scientific from $88.00 to $98.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Truist Financial lifted their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Barclays lifted their target price on shares of Boston Scientific from $78.00 to $86.00 and gave the stock an "overweight" rating in a research report on Thursday, August 22nd. Finally, Sanford C. Bernstein raised their price target on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an "outperform" rating in a report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $93.39.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 162,777 shares of the business's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the transaction, the chief executive officer now owns 1,572,096 shares of the company's stock, valued at approximately $133,046,484.48. The trade was a 9.38 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the business's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total transaction of $585,594.38. Following the completion of the sale, the executive vice president now owns 34,748 shares in the company, valued at approximately $2,913,967.28. This trade represents a 16.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 328,157 shares of company stock valued at $27,957,676 in the last three months. 0.50% of the stock is owned by insiders.

Boston Scientific Trading Up 0.4 %

Shares of BSX traded up $0.39 during midday trading on Wednesday, hitting $90.86. The stock had a trading volume of 3,483,828 shares, compared to its average volume of 6,025,355. The firm has a market cap of $133.90 billion, a PE ratio of 74.77, a price-to-earnings-growth ratio of 2.66 and a beta of 0.80. Boston Scientific Co. has a 1 year low of $53.93 and a 1 year high of $91.93. The stock's 50 day moving average is $86.97 and its 200 day moving average is $81.03. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company had revenue of $4.21 billion for the quarter, compared to analysts' expectations of $4.04 billion. During the same period in the prior year, the business earned $0.50 EPS. The firm's quarterly revenue was up 19.3% on a year-over-year basis. As a group, analysts forecast that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.